Here's Won't Touch Teva: Why I Pass on the Generic Giant
Teva Pharmaceuticals sits at a crossroads of debt, generics, and a shifting pricing landscape. Here's why I won't tou...
Creating a financial plan? Learn what to include to ensure your success and financial stability for the future.
23,717 articlesTeva Pharmaceuticals sits at a crossroads of debt, generics, and a shifting pricing landscape. Here's why I won't tou...
Analysts upgrade CrowdStrike ahead of earnings, citing modest guidance risk and a software sector pullback that has w...
A prominent oil strategist argues the Iran war premium is inflating prices, suggesting oil could trade in the $40s if...
Bitcoin edges higher as XRP and Solana target fresh catalysts. Analysts caution that regulatory moves and new ETF mom...
A new ranking highlights 33 U.S. rifle makers that produced the most rifles in 2022, underscoring domestic manufactur...
Samsung and Apple tied on annual smartphone production in TrendForce’s data, sparking fresh market debate on leadersh...
The NANC ETF, built to mirror congressional disclosure trades, is facing a tougher 2026 as interest rates move higher...
Nvidia has committed $2 billion to Nebius Group, accelerating Nebius’s role in the neocloud era. The move includes ea...
Ethereum faces a potential slide toward $1,500 by the end of the third quarter if bearish momentum persists. CryptoQu...
Bitcoin rose to a weekly high near $72,000 as geopolitical tensions intensified, drawing attention to potential short...
Palantir stock surged as global tensions flare and AI-driven defense angles capture headlines. Yet investors should b...
ChangeNOW has unveiled Private Send, a new privacy feature in NOW Wallet that hides the direct link between sender an...